A Phase 1 First-in-Human Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
